Subscribe to Stay Informed

Subscribe

Updates to Pfizer COVID 19 Vaccine Guidance

The Health Department has received final approvals for the updates to the COVID 19 Pfizer Vaccine in accordance to recommendations by the FDA and CDC.

Here are the changes:

Children 5 – 11 years who are moderately to severely immunocompromised should receive an additional primary dose 28 days after their second dose.  Only Pfizer is approved for those 5 – 11 years of age.

Children are considered to be moderately or severely immunocompromised if they have:

·       Been receiving active cancer treatment

·       Received an organ transplant and taking medication to suppress the immune system.

·       Received a stem cell transplant within the last 2 years or taking medicine to suppress the immune system.

·       Moderate or severe primary immunodeficiency

·       Active or untreated HIV infection

·       Active treatment with high dose corticosteroids or other drug that may suppress the immune system.

All adolescents 12 – 17 years are eligible to and should receive a booster dose 5 months after completing their primary series of the Pfizer vaccine.

Those who have received Pfizer for their initial series can now receive their booster dose beginning at 5 months instead of 6 months.  The booster interval for those who had received Moderna or J&J/Janssen has not changed.